Home Healthcare Pharmaceuticals Pulmonary Arterial Hypertension Market

Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class (Prostacyclin and Prostacyclin Analogs, SGC Stimulators, ERA, PDE-5) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Mitiksha Koul | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Pulmonary Arterial Hypertension Market, By Drug Class 2022-2034 (USD MILLION/ Units)
    1. Prostacyclin and Prostacyclin Analogs
    2. SGC Stimulators
    3. ERA
    4. PDE-5
  2. Regional Pulmonary Arterial Hypertension Market
    1. North America
      1. North America Pulmonary Arterial Hypertension Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      2. U.S.
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      3. Canada
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
    2. Europe
      1. Europe Pulmonary Arterial Hypertension Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      2. U.K.
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      3. Germany
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      4. France
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      5. Spain
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      6. Italy
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      7. Russia
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      8. Nordic
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      9. Benelux
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      10. Rest of Europe
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
    3. APAC
      1. APAC Pulmonary Arterial Hypertension Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      2. China
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      3. Korea
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      4. Japan
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      5. India
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      6. Australia
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      7. Singapore
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      8. Taiwan
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      9. South East Asia
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      10. Rest of Asia-Pacific
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
    4. Middle East and Africa
      1. Middle East and Africa Pulmonary Arterial Hypertension Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      2. UAE
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      3. Turkey
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      4. Saudi Arabia
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      5. South Africa
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      6. Egypt
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      7. Nigeria
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      8. Rest of MEA
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
    5. LATAM
      1. LATAM Pulmonary Arterial Hypertension Market By Drug Class 2022-2034 (USD MILLION/ Units)
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      2. Brazil
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      3. Mexico
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      4. Argentina
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      5. Chile
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      6. Colombia
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
      7. Rest of LATAM
        1. Prostacyclin and Prostacyclin Analogs
        2. SGC Stimulators
        3. ERA
        4. PDE-5
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.